Evolutionary conservation of drug action on lipoprotein metabolism-related targets

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• The clk-1 mutant of Caenorhabditis elegans exhibits defecation behavior defects linked to altered lipoprotein metabolism.
• Lipoprotein metabolism plays a crucial role in various physiological processes.

Purpose of the Study:

• To investigate the genetic and pharmacological basis of defecation defects in clk-1 mutants.
• To explore the potential of C. elegans as a model organism for discovering drugs targeting lipoprotein metabolism.

Main Methods:

• Utilized C. elegans clk-1 mutants to study defecation behavior.
• Administered various drugs affecting lipoprotein metabolism (HMG-CoA reductase, reverse cholesterol transport, HDL levels).
• Conducted a compound screen to identify novel molecules impacting clk-1 mutants and apolipoprotein B secretion in cell lines (HepG2, Caco-2).
• Tested a lead compound (CHGN005) in a mouse model of dyslipidemia.

Main Results:

• Pharmacological interventions targeting lipoprotein metabolism specifically suppressed the defecation phenotype in clk-1 mutants, without affecting wild-type worms or other mutant behaviors.
• A screen identified 190 novel active molecules, with 15 specifically reducing apolipoprotein B secretion in HepG2 cells.
• Compound CHGN005 reduced apolipoprotein B secretion in both HepG2 and Caco-2 cells and decreased plasma cholesterol and triglyceride levels in mice.

Conclusions:

• Defecation defects in clk-1 mutants are directly linked to and correctable by modulating lipoprotein metabolism.
• The identified compounds and the C. elegans model demonstrate conserved lipid-related pathways between nematodes and vertebrates.
• C. elegans serves as a valuable platform for the discovery of novel therapeutic agents targeting lipoprotein synthesis, transport, and metabolism.